Yasunori Kogure
Senior Researcher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (30)
Year:
2026
Year:
2026
Year:
2026
Supplementary Figure S1. Analytical workflow for the C-CAT, GENIE, and TCGA cohorts. Supplementary Figure S2. Comparison of targeted gene panels. Supplementary Figure S3. Comparison of genetic alterations in C-CAT and GENIE cohorts. Supplementary Figure S4. Comparison of mutation frequency, type, and position in C-CAT and GENIE cohorts. Supplementary Figure S5. Co-occurring and mutually exclusive relationships across cohorts. Supplementary Figure S6. Co-occurring and mutually exclusive relationships across cancer types/subtypes. Supplementary Figure S7. Co-occurring and mutually exclusive relationships using a permutation approach. Supplementary Figure S8. Co-occurring and mutually exclusive relationships across driver mutations in epigenetic regulators. Supplementary Figure S9. Functional and prognostic relevance of driver mutations in epigenetic regulators.
Year:
2026
Background Plasma fibrinogen (FNG) is a prognostic marker in esophageal squamous cell carcinoma (ESCC). However, its predictive value for immune checkpoint inhibitor (ICI) efficacy and the underlying mechanisms remain unclear. This study aimed to evaluate the clinical significance of plasma FNG levels in ICI‐treated ESCC patients and investigate its association with tumor‐associated neutrophils (TANs) and genomic alterations. Methods A retrospective, multicenter analysis of 167 ESCC patients treated with ICIs was performed. TANs were quantified via immunohistochemistry using CD11b and CD66b staining, and PD‐L1 expression was assessed using the tumor proportion score (TPS). Whole‐exome and RNA sequencing were conducted to analyze genomic and transcriptomic profiles. Results Elevated plasma FNG levels correlated with lower ICI response rates and decreased survival. In first‐line treatment, chemo‐ICI therapy demonstrated superior efficacy compared to dual‐ICI therapy in high‐FNG patients, while the reverse trend was observed in low‐FNG patients. High‐FNG tumors showed increased TAN infiltration, independent of PD‐L1 expression. RNA sequencing revealed enrichment of neutrophil activation and extravasation pathways in high‐FNG tumors. Conclusions Elevated plasma FNG levels predict poor prognosis and reduced ICI efficacy in ESCC. They may be potential biomarkers for first‐line ICI‐based therapy and correlate with TAN infiltration. Further validation and mechanistic investigations are warranted.
Year:
2026
Using 48,627 samples from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), we present a pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients. Comparison with White patients in Genomics Evidence Neoplasia Information Exchange (GENIE) demonstrates high TP53 mutation frequencies in Asian patients across multiple cancer types. Integration of C-CAT, GENIE, and The Cancer Genome Atlas data reveals many cooccurring and mutually exclusive relationships between driver mutations. At pathway level, mutations in epigenetic regulators frequently cooccur with PI3K pathway molecules. Furthermore, we found significant cooccurring mutations within the epigenetic pathway. Accumulation of mutations in epigenetic regulators causes increased proliferation-related transcriptomic signatures. Loss-of-function of many epigenetic drivers inhibits cell proliferation in their wild-type cell lines, but this effect is attenuated in those harboring mutations of not only the same but also different epigenetic drivers. Our analyses dissect various genetic properties and provide valuable resources for precision medicine in cancer. Significance: We present a genetic landscape of 26 principal cancer types/subtypes, including Asian-prevalent ones, in Japanese patients. Multicohort data integration unveils numerous cooccurring and exclusive relationships between driver mutations, identifying cooccurrence of multiple mutations in epigenetic regulators, which coordinately cause transcriptional and phenotypic changes. These findings provide insights into epigenetic regulator–driven oncogenesis. This article is featured in Selected Articles from This Issue, p. 695
Year:
2026
Year:
2025
Programmed death-ligand 1 (PD-L1/CD274) structural variation (SV) disrupting the 3′-untranslated region has been highlighted as being associated with PD-L1 overexpression. In the present study, we evaluated lymphoma tissue samples to investigate the applicability of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for detecting the PD-L1 SV involving the 3′-untranslated region. In total, 1052 lymphoma samples were screened using IHC, and 99 IHC screening-positive samples were evaluated with FISH (non-Hodgkin lymphoma [NHL, n=58] and Hodgkin lymphoma [HL, n=41]). Of these, 92 samples showed strong PD-L1 expression with 2 PD-L1 antibodies (E1J2J and SP142) (concordant PD-L1 IHC), whereas 7 samples showed strong PD-L1 expression only with E1J2J (discordant PD-L1 IHC). Abnormal FISH findings for PD-L1 were detected in all evaluated samples (51 NHLs and 41 HLs). A structural abnormality pattern was observed in 17 of the 51 evaluated NHL samples (33%). In contrast, all 41 HL samples showed a copy number abnormality pattern, with 1 exhibiting a structural abnormality pattern. Target-capture sequencing of the PD-L1 gene was performed on 73 of the 99 IHC screening-positive samples, comprising 41 NHLs and 32 HLs. PD-L1 SVs were detected in 16 (39%) of the 41 NHL samples and in only one of the 32 HL samples (3%). Samples exhibiting discordant PD-L1 IHC and/or FISH structural abnormality patterns were shown to harbor PD-L1 SV by target-capture sequencing, with positive and negative predictive values of 94% and 96%, respectively. Our approach is an alternative to target-capture sequencing for evaluating PD-L1 gene abnormalities.
Year:
2025
Year:
2025
Phospholipase C gamma 1 ( PLCG1 ) has been identified as the most frequently mutated gene in adult T-cell leukemia/lymphoma, suggesting a critical function of PLCG1 in driving T cell activation. However, it remains unclear how these mutations regulate T cell physiology and pathology. Here, we investigate three common leukemia/lymphoma-associated mutations (R48W, S345F, and D1165H). We discover that these mutations induce hyperactive T cell signaling and cause pro-survival phenotypes. PLCG1 mutants enhance LAT condensation, calcium influx, and ERK activation. They also promote T cell proliferation, upregulate cell adhesion molecules, induce cell aggregation, and confer resistance to Vorinostat, an FDA-approved drug for cutaneous T-cell lymphoma. The resistance depends on ERK signaling and can be reversed with an ERK inhibitor. Interestingly, PLCG1 mutants also induce bystander drug resistance in nearby cells expressing wild-type PLCG1. Mechanistically, alpha smooth muscle actin, which is specifically induced by PLCG1 mutants, directly binds PLCG1 to promote its activation. These results demonstrate that hyperactive PLCG1 promotes T cell survival and drug resistance by inducing non-canonical signaling.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (41)
Katherine Hoadley
Associate Professor
University of North Carolina at Chapel Hill
Claire Palles
Associate Professor
University of Birmingham
Junji Koya
Senior Staff Scientist
National Cancer Center Research Institute
Ines Gockel
University Hospital Leipzig
Johannes Schumacher
Philipps-Universität Marburg
Masaki Iino
Professor
University of Yamanashi Hospital
Axel Hillmer
Assoc. Prof
University Hospital Bonn
Puya Gharahkhani
Team Head, Associate Professor
QIMR Berghofer Medical Research Institute
Takahiro Maeda
Professor
Kyushu University Graduate School of Medical Sciences
Felipe Suarez
Professor
Université Paris-Saclay
Akshay Joshi
University College London
Vahid Asnafi
-
Seishi Ogawa
Kyoto University
Koichi Ohshima
Professor
Kurume University
Takanori Kanai
-
Ian Tomlinson
University of Edinburgh
Keisuke Kataoka
Chief
National Cancer Center Research Institute
Carlo Maj
Head of Bioinformatics | Research Group Leader – Genetic Epidemiology
University of Marburg
Jean‐Marie Michot
-
Sumito Shingaki
New York University
Quinn Ostrom
Assistant Professor
Duke University School of Medicine
David Whiteman
Deputy Director
QIMR Berghofer Medical Research Institute
Beatrice Melin
Professor
Umea University
Hiroaki Miyoshi
Professor
Kurume University
Isabelle André
Université Paris Descartes
Stuart MacGregor
Professor
QIMR Berghofer Medical Research Institute
Dominik Heider
Diretor
University of Münster
Gandhi Damaj
Professor, M.D. Head of departement
University Hospital
David Wedge
The University of Manchester
Niels Olsen Saraiva Camara
Professor Titular
University of Sao Paulo
Helder Nakaya
Associate Professor
University of Sao Paulo
Melissa Bondy
Professor/Department Chair
Stanford University
Yukinori Okada
University of Tokyo
Janusz Jankowski
Professor
University College London
Kazuki Sato
Assistant Professor
University of Tsukuba
Olufunmilayo I. Olopade
Professor
University of Chicago
Laurence de Leval
Director of the Institute of Pathology / Professor of Pathology
Lausanne University Hospital
Sachiko Tsukita
-
Ayumi Fujimoto
Shimane University Hospital
Koji Izutsu
Chief, Department of Hematology
National Cancer Center Hospital
Yuki Saito
National Cancer Center Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.